← Theranostic Atlas Therapy radar Imaging radar All targets Molecules Français Molecules
FAP-2286 Target FAP Class Cyclic peptide (DOTA chelator)
6 ongoing trials
2 radiolabelled forms
0 approved products
91 publications (PubMed)
Structure 3D 2D
Structure from the cited PubChem record (unlabelled ligand, or the labelled form when PubChem only describes that one). Conformer: RDKit (computed conformer, indicative). Rotate with the mouse or a finger.
Properties (PubChem) Molecular formula C67H99N13O18S3 Molar mass (g/mol) 1,470.8 Exact mass (Da) 1,469.6393 XLogP -8.1 H-bond donors 12 H-bond acceptors 25 Rotatable bonds 25 Heavy atoms 101 InChIKey UHKLVUPDBJFFBB-ZCDGVBLYSA-N PubChem record CID 163408889 ↗ IUPAC name (5R,11S,17S,20S,23S,26S,29R)-23-(3-amino-3-oxopropyl)-26-benzyl-5-(hexanoylamino)-20-[(1R)-1-hydroxyethyl]-6,12,18,21,24,27-hexaoxo-35-[2-[[2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetyl]amino]ethylsulfanylmethyl]-3,31-dithia-7,13,19,22,25,28-hexazatetracyclo[31.3.1.07,11.013,17]heptatriaconta-1(37),33,35-triene-29-carboxylic acid SMILES CCCCCC(=O)N[C@H]1CSCC2=CC(=CC(=C2)CSCCNC(=O)CN3CCN(CCN(CCN(CC3)CC(=O)O)CC(=O)O)CC(=O)O)CSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]4CCCN4C(=O)[C@@H]5CCCN5C1=O)[C@@H](C)O)CCC(=O)N)CC6=CC=CC=C6)C(=O)O Radiolabelled forms Form Use Molar mass (labelled form) Ongoing trials Most advanced phase Approval [¹⁷⁷Lu]Lu-FAP-2286 Syntheses and QC ↗ Therapy — 3 Phase 2 — [⁶⁸Ga]Ga-FAP-2286 Syntheses and QC ↗ Imaging — 3 Phase 2 —
Atlas trials whose studied drug or title names this vector, with this radionuclide.
Trial Phase Status Sponsor Countries LuMIERE · [177Lu]FAP-2286 NCT04939610 · Solid tumors (multiple indications) Phase 2 Recruiting Novartis Pharmaceuticals 6 FAP ligands (FAPI) NCT07523607 · Breast Phase 2 Not yet recruiting Odense University Hospital 0 Lu-FAP CUP · [177Lu]FAP-2286 NCT07434180 · Solid tumors (multiple indications) Phase 2 Not yet recruiting Peter MacCallum Cancer Centre, Australia 1 FAUNUS · [177Lu]FAP-2286 NCT06880757 · Bladder / urothelial Phase 2 Not yet recruiting Ankara University 0 FAP ligands (FAPI) NCT04621435 · Solid tumors (multiple indications) Phase 1 Recruiting Thomas Hope 1 FAP ligands (FAPI) NCT07144085 · Solid tumors (multiple indications) Phase 1 Recruiting Yi Tian 1
Published results · 1 2026-09 LuMIERE (phase 1) · earlyWell tolerated up to 9.25 GBq, chosen for phase 2, but only one partial response in 27 patients: the activity of FAP targeting remains to be shown. Clin Cancer Res ↗
91 publications in PubMed for the query below; the most recent:
"FAP-2286"[tiab]
177 Lu-FAP-2286 Targeted Radionuclide Therapy in Advanced Pancreatic Cancer : A Real-World Retrospective Salvage Study Clin Nucl Med, 2026 A Favorable Partial Response in Patients With Glioblastoma Multiforme Following Combined [177Lu]Lu-FAP-2286 and Chemotherapy Clin Nucl Med, 2026 Heterobivalent fibroblast activation protein-targeted Radiotheranostic ligands integrating cyclic peptide and small-molecule motifs for enhanced tumor retention Bioorg Chem, 2026 Novel Covalent FAP-Targeted Radiotherapy Drug Based on DOTA-FAP-2286 for Enhanced Tumor Uptake, Retention, and Therapeutic Efficacy Mol Pharm, 2026 FAP-targeted [(177)Lu]Lu-FAP-2286 radioligand therapy synergizes with the STING agonist diABZI to enhance antitumor immunity in lung cancer Nucl Med Biol, 2026 Combined 177Lu-FAP-2286 Therapy and Chemotherapy in Extraskeletal Ewing Sarcoma With Multiple Metastases Clin Nucl Med, 2026 Combined 177 Lu-FAP-2286 Therapy and Immunotherapy in Metastatic Esophageal Squamous Cell Carcinoma Clin Nucl Med, 2026 177 Lu-FAP-2286 Therapy in a Patient of Advanced Metastatic Malignant Solitary Fibrous Tumor Clin Nucl Med, 2026 Sources: PubChem and PubMed (NCBI), ClinicalTrials.gov and CTIS registries, approvals recorded by the atlas. PubChem data as of 28 October 2026.
Cite this page FAP-2286. Theranostic Atlas, LaRadiopharmacie.fr. Data as of 27 October 2026. https://theranosticatlas.com/molecule/fap-2286/ (accessed [date]).
A monitoring tool with no regulatory value: check every item at its source.